Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and effectiveness [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] - The Momentum Score helps investors capitalize on price or earnings trends, utilizing one-week price changes and monthly earnings estimate changes [6] - The VGM Score combines all three Style Scores, serving as a crucial indicator alongside the Zacks Rank for identifying stocks with strong value, growth, and momentum [7] Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to aid in portfolio creation [8] - Stocks rated 1 (Strong Buy) have achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [9] - There are over 800 top-rated stocks available, making it essential to utilize Style Scores for effective selection [10] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with lower ranks but high Style Scores may still pose risks if they have downward-trending earnings forecasts [12] Company Spotlight: TransMedics Group - TransMedics Group (TMDX) is a medical technology company focused on organ transplant therapy, currently rated 3 (Hold) with a VGM Score of A [13] - TMDX is projected to experience a year-over-year earnings growth of 129.7% for the current fiscal year, making it appealing for growth investors [13][14] - The Zacks Consensus Estimate for TMDX has risen by $0.42 to $2.32 per share, with an average earnings surprise of +45.4% [14]

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact MINNEAPOLIS, Aug. 20 ...

Core Insights - FendX Technologies Inc. has filed a provisional patent application for an "AI Adaptive App Pathogen Detection Platform" aimed at enhancing pathogen detection on surfaces using mobile devices [1][2] - The invention integrates mobile imaging, biosensor technology, and artificial intelligence to provide real-time pathogen detection, targeting both consumer and professional markets [2][3] Company Overview - FendX is focused on developing innovative surface protection solutions to mitigate the spread of harmful pathogens, with a portfolio that includes eco-friendly products like a smart sponge and REPELWRAP™ film [3] - The company holds exclusive agreements for its eco-sponge and licenses for its coating technologies, indicating a strong position in the hygiene-related technology market [3]

技术创新方面，公司2025上半年研发投入1.34亿元，占营收比例45%，持续强化技术领先优势。作为行 业唯一基于全国产算力训练的大模型，星火医疗大模型V2.5国际版于6月发布，并以高分登顶Medbench 榜单，同时在心内科、儿科、呼吸内科综合诊疗能力达到三甲医院主治医生水平；同时，2025年3月首 发"深度推理思考大模型"星火医疗大模型X1，并于7月实现升级，在全科辅助诊断、体检报告解读、健 康咨询、导医导诊等通用医疗任务上持续保持业界大幅领先。 智通财经APP获悉，据港交所公告，讯飞医疗（02506）于8月20日发布2025年中期业绩，上半年公司实 现营收2.986亿元，同比增长30%，毛利1.539亿元，同比增长27%，毛利率稳居51.5%高位，盈利能力和 增长性持续领跑行业。 ...

Core Insights - Stryker Corporation has successfully reaccelerated revenue growth, both organic and overall, while also driving margin expansion, which has led to an expanded valuation multiple [1] Group 1 - The management of Stryker Corporation has managed to reaccelerate revenue growth [1] - The company has achieved margin expansion [1] - These improvements have contributed to an expanded multiple for the company [1]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of €8.6 billion, growing 8.4% reported and 4.8% organic, in line with guidance [38] - Adjusted EPS was €1.26, exceeding the midpoint of guidance by €0.03 [42] - Adjusted gross margin was 65.1%, down 80 basis points year over year, but stable compared to Q4 [38][39] Business Line Data and Key Metrics Changes - Cardiovascular grew 7% this quarter, with cardiac ablation solutions achieving nearly 50% growth [20][21] - Neuroscience grew 3%, with high single-digit growth in neurosurgery and neuromodulation [10][27] - MedSurg grew 2%, with advanced energy showing high single-digit growth [31] - Diabetes grew 8%, driven by the strength of the 780G system and Simplera Sync Sensor in international markets [34] Market Data and Key Metrics Changes - The U.S. market showed slower growth in certain segments, particularly in diabetes and pelvic health, while international markets performed better [61] - CAS growth was particularly strong in the U.S. and Japan, with low 70s growth in the U.S. and low 30s growth internationally [20][21] Company Strategy and Development Direction - The company is focused on accelerating growth through innovation in med tech and has raised its EPS guidance for the full year [6][7] - A planned separation of the diabetes business is expected to sharpen focus on core high-growth opportunities [17][37] - New board committees have been established to enhance focus on growth and operational efficiency [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to accelerate growth throughout fiscal 2026, citing strong demand and a robust product pipeline [6][17] - The company anticipates significant growth from the cardiac ablation solutions and renal denervation segments [12][13] - Management highlighted the importance of operational efficiency and innovation to drive long-term shareholder value [18][46] Other Important Information - The company expects to finalize the national coverage determination for the simplicity procedure for hypertension by October 8 [25] - The company is investing significantly in R&D, with a 7.7% increase in adjusted R&D spending [40] Q&A Session Summary Question: Update on CAS growth and its impact on U.S. growth - Management confirmed confidence in CAS growth, noting strong demand and utilization, and expects it to positively impact U.S. growth in the future [56][60] Question: Impact of new board committees on governance and capital allocation - Management explained that the new committees will provide focused oversight on growth and operational performance, enhancing communication with management [70][72] Question: Commitment to CAS annual sales target - Management reiterated commitment to the $2 billion annual sales target for CAS, indicating strong momentum and confidence in achieving this goal [76][78] Question: Discussion on capital allocation and EPS growth - Management emphasized a renewed focus on value creation, including potential M&A opportunities and increased investment in growth drivers [81][86] Question: Overall portfolio growth expectations - Management indicated that while significant growth drivers are emerging, the overall business will continue to improve, with a focus on maintaining operational efficiency and EPS growth [95][100]

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake ...

Financial Performance - Medtronic reported Q1 FY26 revenue of $8.539 billion, a 6.7% increase compared to Q1 FY25, with organic revenue growth of 4.8%[24] - Adjusted diluted EPS was $1.26, a 2.4% increase year-over-year[24] - The company is raising FY26 EPS guidance and expects high-single digit EPS growth in FY27[15, 58] Segment Performance - Cardiovascular segment revenue reached $3.285 billion, with 7.0% organic growth[21, 40] - Cardiac Ablation Solutions experienced nearly 50% global growth, including over 70% US growth[15, 32, 39] - Neuroscience segment revenue was $2.416 billion, with 3.1% organic growth[21, 45] - Medical Surgical segment revenue totaled $2.083 billion, with 2.4% organic growth[21, 50] - Diabetes segment revenue was $721 million, with 7.9% organic growth[21, 55] Strategic Initiatives - Medtronic is executing strategic portfolio management, including Diabetes separation within 15 months[15, 55] - The company anticipates a net FY26 tariff impact of approximately $185 million, a decrease from the previous estimate of $200-350 million[15] Future Outlook - Medtronic expects revenue growth to accelerate in the second half of the fiscal year due to significant product launches[14, 31] - Cardiac Ablation Solutions is expected to grow even faster in Q2 and H2 due to PFA supply expansion[15]

Core Insights - Medtronic plc reported its first quarter fiscal 2026 financial results, achieving mid-single digit organic revenue growth for the 11th consecutive quarter, with expectations to accelerate growth in the second half of the fiscal year [1][2][3] Financial Performance - The company reported worldwide revenue of $8.578 billion, an increase of 8.4% as reported and 4.8% on an organic basis [3][4] - GAAP operating profit was $1.445 billion with an operating margin of 16.8%, reflecting a 13% increase and a 70 basis point improvement [3][4] - Non-GAAP operating profit was $2.016 billion with a margin of 23.6%, showing a 3% increase but an 80 basis point decrease [3][4] Earnings and Guidance - GAAP net income was $1.040 billion, with diluted earnings per share (EPS) at $0.81, remaining flat, while non-GAAP diluted EPS increased by 2% to $1.26 [4][8] - The company raised its FY26 EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60, and reiterated its organic revenue growth guidance of approximately 5% [7][8][9] Segment Performance - Cardiac Ablation Solutions revenue surged nearly 50%, with a 72% increase in the U.S. driven by pulsed field ablation products [4][5] - The Cardiovascular Portfolio generated $3.285 billion in revenue, a 9.3% increase as reported and 7.0% organic [5][19] - The Diabetes business reported revenue of $721 million, an increase of 11.5% as reported and 7.9% organic [5][19] International and U.S. Revenue - International revenue reached $4.354 billion, a 13.6% increase, while U.S. revenue was $4.224 billion, reflecting a 3.5% increase [22][19] - The Cardiovascular segment in the international market grew by 12.6%, with notable increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic categories [22][19] Operational Efficiency - The company is focused on improving efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth while increasing investments in R&D, sales, and marketing [9][8]

Core Insights - Resmed has elected Nicole Mowad-Nassar to its board of directors, effective August 15, 2025, while thanking Rich Sulpizio for his two decades of service as he retires from the board [1][5]. Group 1: Board Changes - Nicole Mowad-Nassar is currently the President of Specialty and U.S. Therapeutics Operations at AbbVie, managing a $6 billion commercial portfolio across 17 therapeutic areas and overseeing a workforce of 6,000 [2]. - Rich Sulpizio has served on Resmed's board since 2005, chairing the Compensation Committee and serving on the Audit Committee and Nominating and Governance Committee [5][6]. - Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee, standing for reelection at the 2025 Annual Meeting of Stockholders [4]. Group 2: Professional Background - Mowad-Nassar has over 30 years of experience in strategic, commercial, and operational roles within the pharmaceutical and healthcare sectors, with a focus on digital innovation [7]. - At AbbVie, she played a key role in the commercial integration of the $63 billion Allergan acquisition, ensuring continuity in product launches while minimizing operational disruption [3]. Group 3: Leadership Perspectives - Mick Farrell, Resmed's Chairman and CEO, highlighted Mowad-Nassar's extensive experience and commitment to patient access and digital engagement, indicating her potential to enhance the board's strategic direction [4]. - Farrell expressed gratitude for Sulpizio's contributions, noting his energy and people-first mindset during board discussions [6].